Summit Therapeutics (SMMT) Net Cash Flow (QoQ) (2017 - 2026)
Powered by 
Analysis
Summit Therapeutics (SMMT) Net Cash Flow (QoQ) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 363.49% |
| Mar 31, 2026 | -794.47% |
| Dec 31, 2025 | 77.63% |
| Sep 30, 2025 | -168.77% |
| Jun 30, 2025 | -19.07% |
| Mar 31, 2025 | 852.21% |
| Dec 31, 2024 | -82.83% |
| Sep 30, 2024 | 298.45% |
| Jun 30, 2024 | -236.15% |
| Mar 31, 2024 | -120.65% |
| Dec 31, 2023 | 360.88% |
| Sep 30, 2023 | 37.71% |
| Jun 30, 2023 | 94.96% |
| Mar 31, 2023 | -210.06% |
| Dec 31, 2022 | 690.32% |
| Sep 30, 2022 | 440.66% |
| Jun 30, 2022 | -434.94% |
| Mar 31, 2022 | 172.47% |
| Dec 31, 2021 | 64.88% |
| Sep 30, 2021 | -3,123.12% |